Rani Therapeutics Holdings Inc   (RANI)
Other Ticker:  
Price: $3.6900 $-0.05 -1.337%
Day's High: $3.8 Week Perf: 6.96 %
Day's Low: $ 3.63 30 Day Perf: 6.65 %
Volume (M): 139 52 Wk High: $ 6.89
Volume (M$): $ 514 52 Wk Avg: $3.75
Open: $3.77 52 Wk Low: $1.82

 Market Capitalization (Millions $) 94
 Shares Outstanding (Millions) 26
 Employees 100
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 2

Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings Inc is a clinical-stage bio-pharmaceutical company founded in 2012 and headquartered in San Jose, California. The company's core mission is to develop innovative, non-injectable therapies that can be administered orally.

Rani Therapeutics' flagship product is the RaniPill capsule, which is a self-administered drug delivery device designed to replace injections. The RaniPill is packed with tiny needles that are typically made of sugar and dissolve when the capsule is swallowed. When the capsule reaches the stomach, it is designed to inject the medication directly into the intestinal wall where it is absorbed into the bloodstream.

The company is focused on developing oral formulations of large-molecule biologics, such as complex proteins and peptides, which traditionally have to be administered by injection. With its innovative technology, Rani Therapeutics is hoping to change the way medication is delivered, making it easier for patients to receive lifesaving treatment without having to endure painful and inconvenient injections.

In addition to the RaniPill, the company is also developing a range of other novel drug delivery systems, including the RaniNose nasal spray and the RaniPatch transdermal patch.

Rani Therapeutics has received significant financial backing from numerous venture capitalists, including 5AM Ventures, Novartis, and GV (formerly known as Google Ventures). The company has raised more than $142 million to date.

Rani Therapeutics' experienced management team includes highly qualified industry professionals who have a track record of developing and commercializing innovative pharmaceutical products. The company employs over 80 people across its research and development, manufacturing, and business development teams.

Overall, Rani Therapeutics Holdings Inc is a dynamic and growing company that is at the forefront of developing innovative, non-injectable therapies that have the potential to transform the treatment of a range of medical conditions.

   Company Address: 2051 Ringwood Avenue San Jose 95131 CA
   Company Phone Number: 457-3700   Stock Exchange / Ticker: NASDAQ RANI
   RANI is expected to report next financial results on March 21, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Revolutionizing Drug Delivery: Rani Therapeutics' Preclinical Data Shows Promise in Transenteric Delivery of GLP-1 Incretin Triagonist

Published Thu, Dec 14 2023 1:00 PM UTC

In a significant advancement in oral drug delivery, Rani Therapeutics, a pioneer in oral biologics, has revealed compelling preclinical pharmacodynamic data on the transenteric delivery of GLP-1 Incretin Triagonist. This disclosure underscores the immense potential of Rani's cutting-edge drug delivery technology to revolutionize the treatment of metabolic diseases, dram...

Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings Inc Faces Tough Q3 Earnings Season, Raises Concerns for Future Prospects

The third quarter of 2023 has been a challenging period for Rani Therapeutics Holdings Inc, a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs. With a significant operating loss of $-17.855 million and no reported revenue, the company's financial performance raises concerns about its future prospects. Furthermore, Rani Therapeutics' net loss of $-18.332 million for the July to September 2023 period represents a substantial increase compared to the same period the previous year. These developments, coupled with the persistent underperformance of the company's stock, warrant a bearish analysis of Rani Therapeutics Holdings Inc.
Lack of Revenue Generation
The absence of any revenue streams reported by Rani Therapeutics Holdings Inc during the July to September 2023 period is disconcerting. Pharmaceutical companies heavily rely on revenue from their products to sustain their operations, fund research and development, and generate profits for shareholders. Without any signs of substantial revenue generation, Rani Therapeutics' ability to achieve long-term profitability remains uncertain.

Rani Therapeutics Holdings Inc

Surprising Financial Twist Leaves Shareholders Stunned as Rani Therapeutics Holdings Inc Faces Operating Deficit of $-18.294 Million in Second Quarter of 2023

As an investor closely monitoring the financial performance of Rani Therapeutics Holdings Inc, the latest results have left me with mixed feelings. The first quarter of the company's fiscal year 2023 has recorded unexpected changes in revenue, catching shareholders off guard. Furthermore, RANIsn reported operating deficit of $-18.294 million for the April to June 2023 reporting season has raised significant concerns.
The absence of top-line revenues in the recent financial report hinders a comprehensive evaluation of the company's current performance. However, to provide some context, let us observe the same quarter in 2022. During the second quarter of 2022, Rani Therapeutics reported an operating deficit of $-15.847 million, which has now widened notably to $-18.664 million. This increase in the deficit raises questions about the company's ability to effectively navigate its financial landscape.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com